Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Cancer immunology research - 1 Jun 2018

Hu Zhiwei, Shen Rulong, Campbell Amanda, McMichael Elizabeth, Yu Lianbo, Ramaswamy Bhuvaneswari, London Cheryl A, Xu Tian, Carson William E

Abstract excerpt

Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with BRCA1 and BRCA2 mutation. Due to the lack of validated target molecules, no targeted therapy for TNBC is approved. Tissue factor (TF) is a common yet specific surface target receptor for cancer cells, tumor vascular endothelial cells, and cancer stem cells in several types of solid cancers, including breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to CHO Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetulus

Share to Immunoconjugates

Share to Molecular Targeted Therapy

Share to Thromboplastin

Share to Triple Negative Breast Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29622581
DOI: 10.1158/2326-6066.CIR-17-0343
PMCID: PMC5984705

Genes

TF
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.PMID 29622581Read ↗

Advances in immunotherapy for triple-negative breast cancerSemantic proximity Read ↗

BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancerSemantic proximity Read ↗

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.Semantic proximity Read ↗

Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1RSemantic proximity Read ↗

EGFR as a potent CAR T target in Triple Negative Breast Cancer Brain MetastasesSemantic proximity Read ↗

Antibody-Independent Antitumor Effects of Cd32A-Chimeric Receptor T Cells: Implications for Breast Cancer Prognosis and TreatmentSemantic proximity Read ↗

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read ↗

A Phase II Study of Talimogene Laherparepvec for Patients With Inoperable Locoregional Recurrence of Breast CancerSemantic proximity Read ↗

Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.Semantic proximity Read ↗

Tumor-derived FXII engages the intrinsic coagulation cascade to support breast cancer liver metastasisSemantic proximity Read ↗

Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificitySemantic proximity Read ↗

Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.